SG10202000644TA - Improved Stem Cell Composition - Google Patents

Improved Stem Cell Composition

Info

Publication number
SG10202000644TA
SG10202000644TA SG10202000644TA SG10202000644TA SG10202000644TA SG 10202000644T A SG10202000644T A SG 10202000644TA SG 10202000644T A SG10202000644T A SG 10202000644TA SG 10202000644T A SG10202000644T A SG 10202000644TA SG 10202000644T A SG10202000644T A SG 10202000644TA
Authority
SG
Singapore
Prior art keywords
stem cell
cell composition
improved stem
improved
composition
Prior art date
Application number
SG10202000644TA
Inventor
Silviu Itescu
Paul Simmons
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901247A external-priority patent/AU2014901247A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of SG10202000644TA publication Critical patent/SG10202000644TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10202000644TA 2014-04-07 2015-04-07 Improved Stem Cell Composition SG10202000644TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2014901247A AU2014901247A0 (en) 2014-04-07 Improved stem cell composition

Publications (1)

Publication Number Publication Date
SG10202000644TA true SG10202000644TA (en) 2020-03-30

Family

ID=53724311

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202000644TA SG10202000644TA (en) 2014-04-07 2015-04-07 Improved Stem Cell Composition
SG11201607925SA SG11201607925SA (en) 2014-04-07 2015-04-07 Improved stem cell composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201607925SA SG11201607925SA (en) 2014-04-07 2015-04-07 Improved stem cell composition

Country Status (9)

Country Link
US (3) US10400218B2 (en)
EP (2) EP3129468B1 (en)
JP (3) JP6882161B2 (en)
KR (2) KR102405663B1 (en)
CN (2) CN113337462A (en)
AU (5) AU2015243575B2 (en)
CA (1) CA2944262C (en)
SG (2) SG10202000644TA (en)
WO (1) WO2015155187A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202000644TA (en) 2014-04-07 2020-03-30 Mesoblast Int Sarl Improved Stem Cell Composition
KR20230038590A (en) * 2014-06-10 2023-03-20 메조블라스트 인터내셔널 에스에이알엘 Treatment of immune disorders
JP6231709B1 (en) * 2016-05-31 2017-11-15 シスメックス株式会社 Fluorescence image analyzer and analysis method
JP7398959B2 (en) * 2017-05-04 2023-12-15 メゾブラスト・インターナショナル・エスアーエールエル Mesenchymal progenitor or stem cells with improved immunosuppressive properties
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
WO2022020210A1 (en) 2020-07-18 2022-01-27 Ossium Health, Inc. Permeation of whole vertebral bodies with a cryoprotectant using vacuum assisted diffusion
AU2021360590A1 (en) 2020-10-14 2023-06-15 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
EP4262831A1 (en) 2020-12-18 2023-10-25 Ossium Health, Inc. Methods of cell therapies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
EP0986635A4 (en) 1997-01-10 2001-11-07 Life Technologies Inc Embryonic stem cell serum replacement
AU2005209688A1 (en) * 1999-07-07 2005-10-06 Angioblast Systems, Inc. Mesenchymal precursor cell
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
JPWO2004074494A1 (en) * 2003-02-19 2006-06-01 株式会社ディナベック研究所 Treatment method for ischemic disease
EP2361970A1 (en) * 2004-09-24 2011-08-31 Angioblast Systems Incorporated Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
KR101617319B1 (en) 2005-04-12 2016-05-02 메소블라스트, 아이엔씨. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
WO2007122233A1 (en) * 2006-04-25 2007-11-01 Vrije Universiteit Brussel Preparation of mesenchymal progenitor cells, particularly osteogenic progenitor cells
CN101407790B (en) * 2008-10-30 2010-09-29 浙江大学 Processing method for enhancing human medulla ossium mesenchyma stem cell paracrine ability
EP2258413A1 (en) * 2009-06-04 2010-12-08 Université Catholique de Louvain Multi-dimensional biomaterial and method for producing the same.
CN102899293A (en) 2012-11-01 2013-01-30 上海市肺科医院 Mesenchymal stem cells genetically modified with angiopoietin 1 gene and construction method and application thereof
CN106063178B (en) * 2013-12-18 2019-10-18 Idac控股公司 Methods, devices and systems for the interference management in full duplex radio electric system
SG10202000644TA (en) * 2014-04-07 2020-03-30 Mesoblast Int Sarl Improved Stem Cell Composition

Also Published As

Publication number Publication date
CN106459913A (en) 2017-02-22
KR102577698B1 (en) 2023-09-12
CN113337462A (en) 2021-09-03
JP2017512842A (en) 2017-05-25
AU2018200619A1 (en) 2018-02-15
US20170107495A1 (en) 2017-04-20
JP2023021279A (en) 2023-02-10
AU2018200619B2 (en) 2020-01-02
AU2022200640A1 (en) 2022-02-24
EP3129468B1 (en) 2022-09-21
US10400218B2 (en) 2019-09-03
WO2015155187A1 (en) 2015-10-15
CN106459913B (en) 2021-05-18
EP3129468A1 (en) 2017-02-15
US11312941B2 (en) 2022-04-26
CA2944262C (en) 2023-08-01
KR20220080023A (en) 2022-06-14
AU2018200619B9 (en) 2020-05-07
SG11201607925SA (en) 2016-10-28
US20230030428A1 (en) 2023-02-02
JP6882161B2 (en) 2021-06-02
CA2944262A1 (en) 2015-10-15
KR102405663B1 (en) 2022-06-07
JP7196216B2 (en) 2022-12-26
EP4137560A1 (en) 2023-02-22
AU2020202214A1 (en) 2020-04-16
AU2022200640B2 (en) 2024-02-15
AU2024203197A1 (en) 2024-05-30
US20190345452A1 (en) 2019-11-14
AU2020202214B2 (en) 2021-11-18
AU2015243575A1 (en) 2016-10-13
AU2015243575B2 (en) 2017-11-02
KR20160145066A (en) 2016-12-19
JP2021080272A (en) 2021-05-27

Similar Documents

Publication Publication Date Title
IL274903A (en) Cell
ZA201901336B (en) Improved t cell compositions
SG11201607925SA (en) Improved stem cell composition
PL3157504T3 (en) Stem cell stimulating compositions
GB201410905D0 (en) Composition
GB201404178D0 (en) Composition
GB201403017D0 (en) Composition
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
PL3149792T3 (en) Lithium-sulphur cell
SG10201403640XA (en) Stem cells
GB201415483D0 (en) Composition
GB201404390D0 (en) Composition
GB201403550D0 (en) Composition
GB201402648D0 (en) Composition
AU2014901247A0 (en) Improved stem cell composition
GB201416750D0 (en) Cell preparation
GB201410934D0 (en) T cell
GB201412414D0 (en) Composition
GB201412314D0 (en) Composition
GB201402487D0 (en) Composition
GB201401510D0 (en) Composition